Abstract 2168
Background
Carboplatin clearance is correlated with Glomerular Filtration Rate (GFR), which is usually evaluated with creatinine clearance using Cockcroft-Gault (CG) formula. Because serum creatinine (sCR) level is related to total muscle mass, we hypothesized that an abnormal body composition with a low lean body mass (LBM) percentage (LBM / weight) may result in GFR overestimation and inadequate carboplatin dose calculation by using CG formula. Serum cystatin C (sCY) is an alternative marker of GFR which is not affected by muscle mass. We aimed to correlate GFR creatinine (GFRCr) and cystatin C (GFRCy) to LBM percentage and the risk of toxicity. A high GFRCr/GFRCy ratio might estimate the miscalculation of GFR with sCR.
Methods
sCR and sCY were prospectively measured in consecutive cancer patients (pts) before chemotherapy. GFRCr and GFRCy were calculated with CG and GRUBB formula, respectively. The LBM was assessed using CT-scan. Febrile neutropenia and grade 3-4 thrombocytopenia were analysed in a subgroup of pts treated with carboplatin AUC 5 +/- paclitaxel.
Results
In 134 cancer pts (males 51%), median age was 63.7 (20 – 89). In 128 pts without severe renal insufficiency, sCR was correlated with LBM (r = 0.30, Pearson correlation coefficient, p 1.4.
Conclusions
Pts with a low LBM percentage (sarcopenic overweight pts) are at high risk of inadequate calculation of renal function, over dosage of carboplatin and increased acute limiting toxicity. High GFRCr/GFRCy ratio allows to identify these pts.
Clinical trial identification
Legal entity responsible for the study
J. Alexandre
Funding
Fondation Martine Midy
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract